ReCOV

TAIZHOU, CHINA - DECEMBER 23, 2021 - (FILE) A technician performs protein purification of the novel coronavirus vaccine ReCOV at the Reco Biological workshop in Taizhou, Jiangsu province, China, December 23, 2021. On February 13, 2023, REC610, a recombinant shingles vaccine with a new adjuvant, was successfully enrolled in the first batch of subjects.Located in Taizhou China Medical City, Jiangsu Province, Rikbiol has established a high-value innovative vaccine portfolio consisting of more than 10 highly differentiated vaccines, covering the major burden of diseases such as cervical cancer, shingles, COVID-19 and adult tuberculosis. The core product, recombinant HPV nine-valent vaccine REC603, is currently in Phase III clinical trials and is expected to become the first domestic HPV nine-valent vaccine on the market. In addition, ReCOV, a recombinant COVID-19 vaccine that is now very close to commercialization, has become one of the most competitive second-generation COVID-19 vaccines in the world. (Photo credit should read CFOTO/Future Publishing via Getty Images)